Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Raw Materials (2021 - 2025)

Historic Raw Materials for Fortress Biotech (FBIO) over the last 5 years, with Q1 2025 value amounting to $2.8 million.

  • Fortress Biotech's Raw Materials fell 3282.3% to $2.8 million in Q1 2025 from the same period last year, while for Mar 2025 it was $2.8 million, marking a year-over-year decrease of 3282.3%. This contributed to the annual value of $3.2 million for FY2024, which is 3112.07% down from last year.
  • As of Q1 2025, Fortress Biotech's Raw Materials stood at $2.8 million, which was down 3282.3% from $3.2 million recorded in Q4 2024.
  • Fortress Biotech's Raw Materials' 5-year high stood at $8.4 million during Q1 2022, with a 5-year trough of $2.8 million in Q1 2025.
  • Its 5-year average for Raw Materials is $5.2 million, with a median of $5.1 million in 2021.
  • Its Raw Materials has fluctuated over the past 5 years, first soared by 4689.22% in 2022, then plummeted by 3453.12% in 2023.
  • Fortress Biotech's Raw Materials (Quarter) stood at $5.6 million in 2021, then rose by 15.83% to $6.5 million in 2022, then fell by 28.11% to $4.6 million in 2023, then tumbled by 31.12% to $3.2 million in 2024, then dropped by 12.14% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q1 2025, $3.2 million for Q4 2024, and $3.6 million during Q3 2024.